Skip to main content

Advertisement

Table 5 Multivariate analysis of predictive factors for benefit from Metronomic treatment in patients undergoing metronomic zoledronic acid

From: Prognostic and predictive value of clinical and biochemical factors in breast cancer patients with bone metastases receiving "metronomic" zoledronic acid

Clinical and biochemical factor Patient population Multivariate
   Variables in model Backward selection
   HR (99% CI) P HR (99% CI) P
DFI (year) > 2 vs ≤ 2 1.811 (0.788-4.161) 0.026 --
ER status + vs - 0.753 (0.281-2.014) 0.459 --
Numbers of previous chemotherapy ≤ 2 vs > 2 0.414 (0.130-1.136) 0.050 --
Baseline CEA (ug/L) ≤ 10 vs > 10 1.633 (0.629-4.241) 0.186 --
Baseline CA 15-3 (U/mL) ≤ 25 vs > 25 1.283 (0.433-3.800) 0.554 --
Baseline NTx (nM BCE) ≤ 18 vs > 18 1.645 (0.652-4.150) 0.166 2.309 (1.067-5.012) 0.005